Amgen (NQ: AMGN )
255.71 USD +0.58 (+0.23%) Official Closing Price Updated: 7:45 PM EDT, Apr 16, 2021 Add to My Watchlist
Press releases about Amgen
Sports Anchor And Multiple Myeloma Patient Rod Gilmore Joins Amgen's Myeloma MVP™ Team
October 15, 2019
Amgen Foundation Launches Amgen Biotech Experience In Pittsburgh
October 09, 2019
Unique Partnership With the Richard King Mellon Foundation Brings Renowned Science Education Program to Pittsburgh Area High School Students
Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Patients With Solid Tumors At ESMO 2019
September 28, 2019
Heart Attack Survivors Are Taking Steps To Reduce Their Cardiovascular Risk. But Are They The Right Ones?
September 26, 2019
This World Heart Day, Amgen is Releasing Results of a Global Survey of 3,200 Heart Attack Survivors Conducted Across 13 Countries
Amgen To Webcast Investor Call At ESMO 2019
September 25, 2019
Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Society for Medical Oncology (ESMO) 2019 Congress on Saturday, Sept. 28, at 10 a.m. PT. David...
Amgen Announces Positive Results From Two Phase 3 BLINCYTO® (blinatumomab) Studies In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia
September 24, 2019
Phase 3 '215 and Children's Oncology Group (COG) Studies Both Stopped Early Due to Treatment Benefit of BLINCYTO Over Chemotherapy
Amgen Showcases New Data From Oncology Pipeline And Portfolio At ESMO 2019
September 17, 2019
S&P 500 buybacks decline significantly in Q2 2019; expenditures still remain higher than the pre-2018 levels
September 16, 2019
- Q2 2019 share repurchases were $164.5 billion - 20.1% lower than Q1 2019, 13.7% lower than Q2 2018, and 26.2% lower than the record Q4 2018.
Amgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference
September 13, 2019
Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:45 a.m. British Summer Time on Wednesday, Sept. 18, 2019, in London. David W. Meline, executive...
Amgen Announces Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) Meets Primary Endpoint Of Progression-Free Survival
September 13, 2019
First Phase 3 Study Combining KYPROLIS and DARZALEX, Two Critical Mechanisms of Action in Treatment of Multiple Myeloma
Amgen Highlights New Data From KYPROLIS® (carfilzomib) And Oncology Pipeline At IMW 2019
September 12, 2019
deCODE in Iceland Agrees to Sequence Half of UK Biobanks Participants
September 11, 2019
deCODE genetics in Iceland has entered into an agreement with a consortium of government, charity, researchers and world leading biopharmaceutical and healthcare companies to undertake whole genome...
Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Larger Patient Group At WCLC 2019
September 08, 2019
54% of 13 Evaluable Non-Small Cell Lung Cancer Patients Experienced a Partial Response at the Target Dose of 960 mg in the Ongoing Phase 1 Study
Amgen To Present At The Morgan Stanley Global Healthcare Conference
September 05, 2019
Amgen (NASDAQ: AMGN) will present at the Morgan Stanley Global Healthcare Conference at 9:10 a.m. ET on Tuesday, Sept. 10, 2019, in New York City. Robert A. Bradway, chairman and chief executive...
Amgen To Webcast Investor Call At IASLC 2019 World Conference on Lung Cancer
September 04, 2019
Amgen (NASDAQ:AMGN) will host a webcast call for the investment community at the International Association for the Study of Lung Cancer (IASLC) 2019 World Conference on Lung Cancer (WCLC) on Sunday,...
New Amgen Data To Be Presented At ESC Congress 2019 Highlight Additional Evidence For Repatha® (Evolocumab) Effectiveness In Cardiovascular Disease Across Multiple Patient Groups
August 28, 2019
Amgen to Host Health Screening and Education Program at ESC Congress Public Event in Paris to Help Identify Patients at Risk for Cardiovascular Events
Amgen To Acquire Otezla® For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefits
August 26, 2019
Bristol-Myers Squibb Announces Agreement Between Celgene and Amgen to Divest OTEZLA® for $13.4 Billion
August 26, 2019
Bristol-Myers Squibb Company (NYSE: BMY) announced today that Celgene Corporation (NASDAQ: CELG), in connection with its merger agreement with Bristol-Myers Squibb, has entered into an agreement with...
Amgen And Allergan Announce Positive Top-Line Results From Comparative Clinical Study Of ABP 798, Biosimilar Candidate To Rituxan® (Rituximab)
August 22, 2019
Study Evaluated Efficacy and Safety of ABP 798 Compared to Rituxan in Patients With Non-Hodgkin's Lymphoma
Record Revenues, Milestone Achievements Indicate Strength, Potential of Biotech Sector
August 21, 2019
Amgen Wins Patent Case On Enbrel® (etanercept)
August 09, 2019
Amgen Announces 2019 Third Quarter Dividend
August 02, 2019
Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.45 per share dividend for the third quarter of 2019. The dividend will be paid on Sept. 6, 2019, to all stockholders of...
Amgen Reports Second Quarter 2019 Financial Results
July 30, 2019
Amgen (NASDAQ: AMGN) today announced financial results for the second quarter of 2019. Key results include:
Amgen Controls 98% Of The Shares In Nuevolution After The End Of The Extended Acceptance Period
July 26, 2019
Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Tuesday, July 30, 2019, after the close of the U.S. financial markets. The announcement will be followed...
Amgen And Allergan's MVASI™ (bevacizumab-awwb) And KANJINTI™ (trastuzumab-anns) Now Available In The United States
July 18, 2019
Amgen, Novartis And Banner Alzheimer's Institute Discontinue Clinical Research Program With BACE Inhibitor CNP520 For Alzheimer's Prevention
July 11, 2019
After Review of Clinical Data, the Sponsors Concluded That the Potential Benefit for Participants in the Studies Did Not Outweigh the Risk
Amgen Announces The Outcome Of The Recommended Public Cash Offer To The Shareholders Of Nuevolution, Declares The Offer Unconditional And Completes The Offer
July 08, 2019
Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that the companies have been informed the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...